The University of Texas MD Anderson Cancer Center today announced Kimberly Hoggatt Krumwiede, Ph.D., as dean of MD Anderson’s School of Health Professions (SHP), effective Aug. 1.
A Phase II clinical trial of poziotinib for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 mutations, led by researchers at The University of Texas MD Anderson Cancer Center, found the drug had significant antitumor activity and the efficacy was highly dependent on the location of the exon 20 loop insertion, which may impact future clinical trials for EGFR exon 20 targeted therapies.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a lower-intensity therapy for acute myeloid leukemia, a new target for treating chronic myelomonocytic leukemia, real-world synthetic controls for clinical trials in rare cancers, a potential biomarker to predict endocrine therapy response in breast cancer, integrated CRISPR screens to identify novel tumor suppressors, and a deeper knowledge of the immune tumor microenvironment in melanoma-derived brain metastases.
MD Anderson and Turning Point Therapeutics announced a strategic research and development alliance to evaluate Turning Points investigational targeted therapies against ROS1, NTRK, MET and other cancer drivers.
MD Anderson, Invectys and CTMC announced a strategic collaboration to develop CAR T cell therapies targeting HLA-G for treating solid tumors.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include preclinical discoveries for combination therapies to treat breast, ovarian and colorectal cancers; a new treatment target for rare sarcomas; a novel CRISPR engineering approach to facilitate in vivo research; and multiple studies of signal pathways that enhance anti-tumor immune responses.
Androgen receptor (AR) signaling affects response to BRAF/MEK inhibitor therapy in both males and females with melanoma, researchers from The University of Texas
Researchers have developed a mathematical tool to estimate tumor-specific RNA levels from tumor samples with mixed cell types. Using this technique on thousands of samples found that higher mRNA levels are correlated with shorter survival.
A new genetic study discovered that not all breast cancers that develop after DCIS arise from the original DCIS lesion. Roughly 1 in 5 are new cancers, genetically unrelated to the original DCIS.
Results from three early-stage clinical trials led by researchers at The University of Texas MD Anderson Cancer Center show promising activity with novel immunotherapies and targeted therapies for patients with advanced tumors.
Two studies led by The University of Texas MD Anderson Cancer Center that shed new light on the potential of the gut microbiome as a targetable biomarker to improve responses to immunotherapy were presented today at the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting.
Promising clinical results with cellular therapies for patients with blood cancers highlight advances being presented by researchers from The University of Texas MD Anderson Cancer Center at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. These findings include long-term outcomes of patients receiving an infusion of brexucabtagene autoleucel (KTE-X19) for mantle cell lymphoma, efficacy of gamma delta CAR T therapy for aggressive B-cell lymphoma and responses of umbilical cord blood-derived expanded natural killer cells when given together with combination therapy before stem cell transplant.
In a Phase II clinical trial, immune checkpoint blockade before surgery was associated with favorable responses and outcomes in undifferentiated pleomorphic sarcoma (UPS) and recurrent dedifferentiated liposarcoma (DDLPS), researchers from The University of Texas MD Anderson Cancer Center reported today at the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting.
Eduardo Bruera, M.D., chair of Palliative Care Medicine at The University of Texas MD Anderson Cancer Center, has received the American Society of Clinical Oncology (ASCO) Walther Cancer Foundation Supportive Oncology Award. Bruera was formally recognized today at the 2022 ASCO Annual Meeting during the Mentorship and Career Development Roundtable.
Combination chemoimmunotherapy with the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated mantle cell lymphoma (MCL) in patients 65 and over, researchers from The University of Texas MD Anderson Cancer Center reported today at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The study results also were published today in the New England Journal of Medicine.
MD Anderson and Resilience today announced the launch of a joint venture, the Cell Therapy Manufacturing Center, which unites the strengths of both parties to accelerate the development and manufacturing of cell therapies for patients with cancer.
Current advances include new biomarkers to predict chimeric antigen receptor (CAR) T cell therapy outcomes and neurotoxicities, novel treatment targets for pre-cancerous pancreatic lesions and T-cell acute lymphoblastic leukemia, a new approach to improve immunotherapy responses in cold tumors, a profile of synthetic lethal targets for cancers with tumor suppressor loss, and promising clinical data for acute myeloid leukemia and cancers of unknown primary.
Researchers at The University of Texas MD Anderson Cancer Center have developed an ultrasound-guided cancer immunotherapy platform that generates systemic antitumor immunity and improves the therapeutic efficacy of immune checkpoint blockade. The findings from the preclinical study were published today in Nature Nanotechnology.
This special edition features upcoming oral presentations by MD Anderson researchers at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting focused on quality improvement, health services research, new treatments for skin cancers, and symptoms and survivorship advances. More information on ASCO content from MD Anderson can be found at MDAnderson.org/ASCO.
Current discoveries include a novel target for mutant colorectal cancers, advances in breast cancer metastases to the brain and bone, a new understanding for secondary leukemias, biomarkers for myelofibrosis treatment response, a computational tool for combining single-cell datasets, unique immune features of pre-cancerous pancreatic cysts, encouraging clinical results for Ewing sarcoma and a new protein critical for T cells to mount an anti-tumor immune response.
Adolescent and young adult survivors of acute lymphoblastic leukemia and acute myeloid leukemia, two of the most common leukemias for ages 15 to 39 years old, have increased risk of mortality than the general population for decades after initial diagnosis. Researchers investigated disparities specific to survivorship to learn about patients’ outcomes after they survived their initial diagnosis; and analyzed data from cancer survivors who were at least five years post treatment. Results suggest there is a gap in critical data surveillance that needs to be examined to further understand what is impacting long-term survivorship for AYAs.
Researchers at The University of Texas MD Anderson Cancer Center have identified a novel strategy to reduce immune-related adverse events from immunotherapy treatment by targeting the cytokine interleukin-6 (IL-6).
Featured studies include clinical advances with a new combination therapy targeting angiogenesis in platinum-resistant ovarian cancer and a promising immunotherapy combination for kidney cancer, plus laboratory studies that focus on targeting ferroptosis in specific lung cancers, developing chimeric antigen receptor (CAR) T cell therapies for blastic plasmacytoid dendritic cell neoplasms, and characterizing racial and ethnic disparities in breast cancer early detection.
The University of Texas MD Anderson Cancer Center and Indianapolis-based Community Health Network today announced a partnership agreement to create Community Health Network MD Anderson Cancer Center. A comprehensive clinical and research cancer program collaboration in central Indiana, Community MD Anderson will provide Hoosier cancer patients greater access to some of the most advanced oncology care.
MD Anderson awarded more than $10 million in grants to support collaborative research teams working to advance novel interception and treatment strategies that will improve outcomes for several cancer types with the greatest unmet need, including pancreatic cancer, ovarian cancer and glioblastoma (GBM).
Using retrospective clinical data and in-depth lab studies, researchers have discovered that vitamin E can enhance immunotherapy responses by stimulating dendritic cells in the tumor.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current studies include clinical advances with immunotherapy combinations and quality of life for breast cancer patients plus molecular subtypes for liver cancer, new treatment targets in bladder cancer, mechanisms driving immune-related side effects, and the effects of specific gene mutations on p53 activity.
Researchers have developed a new computational tool to select optimal combination therapies for patients with cancer based on the co-occurring alterations in a given tumor.
The University of Texas MD Anderson Cancer Center today named Ranna Parekh, M.D., chief diversity, equity and inclusion officer (CDEIO). Parekh will begin her role on May 31.
Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer.
New data from MD Anderson-led studies on ATR inhibitor and next-generation PARP1 inhibitor presented at AACR Annual Meeting
Researchers from The University of Texas MD Anderson Cancer Center showed that natural killer (NK) cells derived from donated umbilical cord blood, combined with a novel bispecific antibody known as AFM13 that targets CD16A and CD30, achieved effective responses in patients with pretreated and refractory CD30+ lymphoma. The study was presented today at the American Association for Cancer Research (AACR) Annual Meeting 2022.
This special edition features presentations by MD Anderson researchers at the AACR Annual Meeting 2022, including early-stage clinical trials on immunotherapy and targeted therapies plus laboratory studies to improve immunotherapy responses, to understand early lung cancer development, to clarify the role of ZEB1 in lung cancer metastasis and to develop new treatments for cancers with KRAS mutations.
Researchers discovered that two distinct classes of fibroblast cells accumulate in pancreatic tumors and play opposing roles to promote and restrain pancreatic cancer growth. Appropriately targeting these cells may offer options to improve treatment outcomes.
The Allison Institute is a visionary research and innovation hub within MD Anderson launched to foster groundbreaking science, to advance new treatments and to bring the benefits of immunotherapy to all patients.
A multicenter research team co-led by The University of Texas MD Anderson Cancer Center developed the first drug to treat the uncontrolled secretion of mucins in the airways, which causes potentially life-threatening symptoms in millions of Americans with common lung diseases.
The University of Texas MD Anderson Cancer Center will make a special announcement at 9 a.m. on Thursday, March 24, about institutional efforts to usher in a new era for immunotherapy. The announcement live stream will be available at www.MDAnderson.org. Opportunities are available for interviews following the announcement.
Neal G. Copeland, Ph.D., and Nancy A. Jenkins, Ph.D., both professors of Genetics at The University of Texas MD Anderson Cancer Center, have been elected to the 2022 class of Fellows of the American Association for Cancer Research (AACR) Academy.
Key presentations focused on genomic sequencing, standard of care approaches for cervical cancer, disparities in oncofertility and new mutations for targeted therapy
Results from the ZUMA-12 trial led by researchers at The University of Texas MD Anderson Cancer Center showed that first-line treatment with axicabtagene ciloleucel (axi-cel), a chimeric antigen receptor (CAR) T cell therapy, achieved a high rate of complete response in patients with high-risk large B-cell lymphoma (LBCL). The study was published today in Nature Medicine, and results recently were presented at the 2021 American Society of Hematology (ASH) meeting.
A new computational approach developed by researchers at The University of Texas MD Anderson Cancer Center successfully combines data from parallel gene-expression profiling methods to create spatial maps of a given tissue at single-cell resolution. The resulting maps can provide unique biological insights into the cancer microenvironment and many other tissue types.
A study led by researchers from The University of Texas MD Anderson Cancer Center showed a significant overall survival benefit with ribociclib plus endocrine therapy for postmenopausal patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. The results were published today in The New England Journal of Medicine and were first reported at the European Society for Medical Oncology (ESMO) Congress 2021.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current findings include immunotherapy advances for AML, liver cancer, HPV-related cancers and other solid tumors, biomarkers of response to TIL therapy in melanoma, a greater understanding of the cells regulating skin wound repair, and data confirming the safety of proton therapy for pediatric brain cancer.
Researchers from The University of Texas MD Anderson Cancer Center discovered that treatment resistance in patients with myelodysplastic syndromes (MDS) is caused by two distinct classes of stem cells and identified possible therapeutic approaches that target these cells. Their findings, which could have significant benefits for patients with disease progression, were published today in Nature Medicine.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current findings include targeted therapies for tumors with PIK3CA and FGFR mutations, a promising combination therapy for myelofibrosis, a new target to improve immunotherapy response in pancreatic cancer, a novel method of increasing chemoradiation sensitivity in glioblastoma, and greater understanding of the chronic lymphocytic leukemia immune microenvironment.
Researchers developed a radio-labeled molecule that allows real-time PET imaging of inflammation and activation of innate immune activity. This would allow physicians to pinpoint areas of inflammation in a variety of clinical settings before symptoms appear.
The University of Texas MD Anderson Cancer Center was awarded $31.73 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of clinical, translational and prevention research across the institution. In total, MD Anderson received more than 28% of the $112.8 million in awards announced by CPRIT.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include a classification system to identify clinically actionable gene fusions, an improved method to culture tumor-infiltrating lymphocytes for non-small cell lung cancer and an effective combination therapy for patients with acute myeloid leukemia carrying specific mutations.
The University of Texas MD Anderson Cancer Center celebrates World Cancer Day, Feb. 4, in honor of the global initiative to end cancer.
A study led by researchers at The University of Texas MD Anderson Cancer Center reported that the MEK inhibitor trametinib reduced the risk of disease progression or death by 52% compared to standard-of-care therapies for the treatment of low-grade serous ovarian carcinoma. The findings were published today in The Lancet.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right